GPR87 promotes renal tubulointerstitial fibrosis by accelerating glycolysis and mitochondrial injury.

Renal tubulointerstitial fibrosis is the hallmark of chronic kidney disease (CKD) and the best predictor of renal survival. However, current treatments for CKD remain extremely limited. Therefore, novel therapeutic targets are urgently needed to either stop or reverse CKD progression.